cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sangamo Therapeutics Inc
14 own
11 watching
Current Price
$3.67
$0.11
(3.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
594.24M
52-Week High
52-Week High
6.42
52-Week Low
52-Week Low
2.721
Average Volume
Average Volume
1.52M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization594.24M
icon52-Week High6.42
icon52-Week Low2.721
iconAverage Volume1.52M
iconDividend Yield--
iconP/E Ratio--
What does the Sangamo Therapeutics Inc do?
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Read More
How much money does Sangamo Therapeutics Inc make?
News & Events about Sangamo Therapeutics Inc.
Business Wire
3 months ago
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest...
Zolmax
9 months ago
DekaBank Deutsche Girozentrale boosted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO Get Rating) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,900 shares of the biopharmaceutical ...
Ticker Report
10 months ago
Equities analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO Get Rating) will post ($0.32) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sangamo Therapeutics earnings. The lowest ...
PR Newswire
10 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fiduciary Duty...
Zolmax
10 months ago
StockNews.com began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a hold rating on the biopharmaceutical companys stock. Other equities analysts have also recently ...
Frequently Asked Questions
Frequently Asked Questions
What is Sangamo Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sangamo Therapeutics Inc shares?
plus_minus_icon
How can I buy Sangamo Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sangamo Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sangamo Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sangamo Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sangamo Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sangamo Therapeutics Inc?
plus_minus_icon
What percentage is Sangamo Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sangamo Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.67
$0.11
(3.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00